The results showed no significant PFS improvement in R/M HNSCC patients without PD-L1 selection who were treated with immunotherapy compared to SOC (HR=1.13, 95% CI: 0.98-1.31). The gene discussed is CD274; the disease is head and neck squamous cell carcinoma.